Commission's appeal against COVID vaccine contract disclosures should be dismissed, court adviser says (updated)

Pfizer

11/06/2026 10:35

Adds comment from Commission spokesperson in sixth paragraph

    BRUSSELS, June 11 (Reuters) - The European Commission's appeal against a 2024 ruling forcing it to disclose information about COVID-19 vaccine contracts should be dismissed, an adviser to Europe's top court said on Thursday.
The Commission negotiated multi-billion vaccine contracts with drug makers such as Pfizer PFE.N and BioNTech 22UAy.DE on behalf of the 27-nation bloc during the pandemic.
In subsequent disclosures the Commission redacted names of a negotiation team and some contractual clauses, arguing protection of privacy of individuals and protection of commercial interests of the companies. The appeal was against the General Court's ruling against that decision.
"The General Court was correct in holding that the transparency of the process of negotiating agreements for Covid-19 vaccines constitutes a specific purpose in the public interest within the meaning of EU law," Advocate General Athanasios Rantos said, according to a court document released on Thursday.
In both cases, the Commission's attitude does not allow accountability, Rantos, whose opinion is not binding, added. 
The Commission said it takes note of Rantos' opinions and awaits the outcome of its appeal.
Rantos' recommendation is a setback for the Commission and its President Ursula von der Leyen, who was at the helm during the COVID crisis. The issue has been used against her in criticism that the EU's executive body under her leadership lacks transparency. 
In a separate case, the General Court ruled in 2025 that the Commission had to disclose text messages between von der Leyen and the CEO of Pfizer during negotiations for COVID vaccines.
The Commission did not provide credible reasons for rejecting a New York Times request to hand over the texts, which von der Leyen said she no longer has. The Commission did not appeal that ruling.        

 (Reporting by Inti Landauro; Editing by Bart Meijer and Elaine Hardcastle)
 ((Inti.Landauro@thomsonreuters.com;))